Combining advanced treatments for high risk prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and effectiveness of a comprehensive treatment approach for high risk prostate cancer by combining hypofractionated pelvic radiotherapy with a focal boost to the primary tumor and reducing androgen deprivation therapy. The study will involve men diagnosed with high risk prostate cancer who require elective lymph node irradiation. Researchers will compare oncological outcomes and toxicity levels against a matched contemporary control group. The goal is to determine if this optimized treatment can improve patient outcomes while minimizing side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men (aged ≥18 years of age) diagnosed within 6 months before inclusion with high risk prostate cancer:

  * T3 based on digital rectal examination AND/OR
  * Grade \>= 4 AND/OR
  * PSA \>=20 ug/L
* Indication for elective lymph node irradiation (based on current clinical guidelines) OR N1 on imaging (with a maximum of 4 suspect lymph nodes)

Exclusion Criteria:

* Prior pelvic radiotherapy
* TransUrethral Resection of the Prostate (TURP) \< 3 months ago
* Prostatectomy or other primary treatment for prostate cancer (e.g. HIFU, cryotherapy, etc)
* contraindications to MRI
* no visible lesion on MRI in prostate for boost
* no PSMA-PET scan
* inflammatory bowel disease
* metastatic disease (M1)
* PSA \>50
* unsuitable for SBRT or WPRT
* medical history of cancer other than basal cell carcinoma of the skin

Where it's running

• Haaglanden Medical Centre
  Leidschendam, South Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Leonard P Bokhorst, MD, PhD — Haaglanden Medical Centre
• Study coordinator: Ursula J Fisscher, PhD
• Email: u.fisscher@haaglandenmc.nl
• Phone: 0031889792357

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Darolutamide with standard or higher-dose targeted prostate radiotherapy plus hormone therapy for men with high-risk localized prostate cancer

  This trial tests whether adding darolutamide and/or using higher-dose targeted prostate radiotherapy together with hormone therapy and pelvic nodal radiotherapy helps men with localized high‑risk prostate cancer stay free of metastatic disease longer.

  Recruiting at 6 sites Phase 3 Unicancer · Brest and 5 other locations · NCT06625970

• Safety of increased radiation doses with hormone therapy for high-risk prostate cancer

  This study is testing if giving higher doses of radiation along with hormone therapy can help men with high-risk prostate cancer without causing too many side effects.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT06461793

• Using complement inhibition to reduce inflammation after subarachnoid hemorrhage

  This study is testing if a new treatment can help reduce inflammation and improve recovery in patients with bleeding in the brain caused by an aneurysm.

  Recruiting Phase 2 Haaglanden Medical Centre · The Hague, South Holland · NCT06359782

• New treatment method for brain metastases using fractionated stereotactic radiotherapy

  This study is testing a new way to treat brain metastases using a different form of radiation therapy to see if it can reduce side effects while still helping patients live longer and feel better.

  Recruiting Haaglanden Medical Centre · Leidschendam, South Holland · NCT05346367

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.